Relation Of Serum Tetranectin with Pathogenicity of Chronic Hypertension Patients in Kirkuk City

Abstract

Background: Hypertension has been identified by WHO as one of the most significant risk factors for morbidity and mortality worldwide and is responsible for the deaths of approximately nine million people annually Aim of the study: The aim of this study was to evaluate the relation of serum tetranectin, atrial natriuretic and other biochemical parameters with hypertension and possibility of use these parameters in development of hypertension Material and Methods: The current study is case control study conducted on 90 Iraqi participants (25-85years) during the period between 10th of January to 10th of April 2022, participants from in Kirkuk city. The study included 60 patients previously diagnosed with hypertension who’s from both sexes whose age were between 36 and 85 years. Hypertension, defined as a systolic blood pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg or are taking medication for hypertension. These patients included when attended to Kirkuk General Hospital. The study also included 30 healthy individuals with same age range and from both sexes who apparently haven’t any chronic diseases. Blood samples collected for determination of of human Tetranectin and ANP by enzyme-linked immunosorbent assay (ELISA). Results: The study showed that the mean of tetranectin was (116.4 pg/ml) in patients with hypertension which was significantly lowest that than in the healthy control group (148.6 pg/ml) at P. value: 0.003. The study no correlation of tetranectin with each of cholesterol and triglyceride, HDL, LDL and VLDL among hypertensive patients. It was concluded that the lowest means of tetranectin was in patients with hypertension and advice to use tetranectin as predictor for hypertension and management tool in cardiovascular disease.